Code: MTA4453 | Publication Date: Jun 2025 |
This growth is attributed to rising chronic diseases, increased awareness of preventive healthcare, and expanding infrastructure across Tier-II and Tier-III cities. The shift towards digitized and AI-supported diagnostic platforms is also accelerating the market’s scale and accessibility.
The diagnostics market in India is expected to witness steady growth, supported by a shift from unorganized to organized sector (chains vs standalone labs), expansion of automated labs and centralized processing centers, greater emphasis on molecular diagnostics, genomics, and AI-based radiology, increased penetration in non-metro regions through PPP models and mobile labs, integration of diagnostics with primary care delivery models and health-tech platforms.
The diagnostic market in India is undergoing a digital and structural change marked by rapid adoption and policy-operated development. AI integration is playing an important role, in which startups such as Qure.AI and Niramai take advantage of artificial intelligence to increase the speed and accuracy of radiology and breast cancer, especially in underscribed areas. Home and point-off-care tests are also increasing, with the use of rapid clinical kits, portable ECG devices and glucose monitors, make the basic healthcare more accessible from the comfort of patients' homes. Meanwhile, Dr. Major clinical series such as red pathlabs, metropolis, and Radcliffe Labs are running a lab consolidation by creating a centralized, technical-competent testing hub to promote operational efficiency. The government's production is accelerating domestic construction of linked incentive (PLI) scheme and diagnostic devices and reagents, aims to reduce dependence on imports. Additionally, diagnostics are getting more integrated with digital health platforms, with spontaneous connections for telemedicine apps and electronic health records, reaching both across the country and improving patient engagement across the country.